Plexxikon Incwas A Biotechnology Company Focused On Drug Discovery Through Structural Biologyfounded In 2001 And Headquartered In Berkeleycaliforniait Later Moved To South San Franciscothe Company Became A Subsidiary Of Daiichi Sankyo After Being Acquired In 2011 For $805 Millionplexxikon Closed Its Operations On March 312022 The Company Specialized In Scaffold Based Drug Discoveryutilizing High Throughput X Ray Crystallography To Identify Chemical Scaffolds For Drug Developmentplexxikon Developed Several Key Productsincluding Vemurafenibzelborafaan Fda Approved Braf Inhibitor For Metastatic Melanomaand Pexidartinibturalioaan Fda Approved Csf1R Inhibitor For Tenosynovial Giant Cell Tumorsthe Company Also Worked On Investigational Drugs Like Plx7486 And Indeglitazarplx204Plexxikon Collaborated With Notable Partners Such As Genentech Roche And Wyeth Pharmaceuticalscontributing To Advancements In Oncology And Metabolic Disorder Treatmentsat The Time Of Its Closureplexxikon Had Filed 122 Patentsprimarily Related To Kinase Modulators And Cancer Therapeutics
No conferences found for this company.
| Company Name | Plexxikon Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
